TNFSF11 and osteoporosis: The critical role of RANKL in osteoporosis is now well-established by the efficacy of denosumab, a human monoclonal anti-RANKL antibody, that specifically inhibits the interaction between RANKL and RANK, in postmenopausal osteoporosis (10).